TW201127959A - Method of producing immune killer cell - Google Patents
Method of producing immune killer cell Download PDFInfo
- Publication number
- TW201127959A TW201127959A TW099104629A TW99104629A TW201127959A TW 201127959 A TW201127959 A TW 201127959A TW 099104629 A TW099104629 A TW 099104629A TW 99104629 A TW99104629 A TW 99104629A TW 201127959 A TW201127959 A TW 201127959A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- medium
- killer
- cell
- killer cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 103
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 6
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000001885 phytohemagglutinin Effects 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 108010062580 Concanavalin A Proteins 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 26
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099104629A TW201127959A (en) | 2010-02-12 | 2010-02-12 | Method of producing immune killer cell |
| US13/024,087 US9222072B2 (en) | 2010-02-12 | 2011-02-09 | Manufacturing method of immune killer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099104629A TW201127959A (en) | 2010-02-12 | 2010-02-12 | Method of producing immune killer cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201127959A true TW201127959A (en) | 2011-08-16 |
| TWI403581B TWI403581B (cg-RX-API-DMAC10.html) | 2013-08-01 |
Family
ID=44369914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099104629A TW201127959A (en) | 2010-02-12 | 2010-02-12 | Method of producing immune killer cell |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9222072B2 (cg-RX-API-DMAC10.html) |
| TW (1) | TW201127959A (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| CN111019892A (zh) * | 2019-12-16 | 2020-04-17 | 杭州恩格生物医疗科技有限公司 | 一种免疫细胞体外诱导扩增方法 |
| CN112251405A (zh) * | 2020-10-15 | 2021-01-22 | 大连天星生物技术有限责任公司 | 一种体外高效诱导扩增nk细胞的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
| CN1245504C (zh) | 2003-12-19 | 2006-03-15 | 上海伯瑞生物技术发展有限公司 | 一种cik细胞体外培养方法 |
| CN101495620A (zh) * | 2006-08-01 | 2009-07-29 | 阿利健制药有限公司 | Lak细胞的增殖方法 |
| CN101314764A (zh) * | 2008-06-24 | 2008-12-03 | 蚌埠医学院 | 一种体外扩增自然杀伤细胞的方法 |
-
2010
- 2010-02-12 TW TW099104629A patent/TW201127959A/zh unknown
-
2011
- 2011-02-09 US US13/024,087 patent/US9222072B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110201114A1 (en) | 2011-08-18 |
| US9222072B2 (en) | 2015-12-29 |
| TWI403581B (cg-RX-API-DMAC10.html) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107488235B (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| CN105886469B (zh) | Cik细胞及其培养方法和应用 | |
| BR112020015512A2 (pt) | método de produção de células exterminadoras naturais e composição para tratamento de câncer | |
| CN107109363A (zh) | 增强对异常细胞杀伤力的方法和药物组合物 | |
| CN102212505B (zh) | 免疫杀手细胞及其制造方法,包含其的医药组成物及套组 | |
| AU2012250807A1 (en) | Induction of IL-12 using immunotherapy | |
| CN105983097B (zh) | 一种抗肿瘤制剂及其制备方法 | |
| CN113244273A (zh) | 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用 | |
| US9222072B2 (en) | Manufacturing method of immune killer cells | |
| AT412145B (de) | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen | |
| CN108815188A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| CN114058580A (zh) | 体外增殖自然杀伤细胞及自然杀伤t细胞的方法 | |
| US7776324B2 (en) | Cancer vaccine | |
| CN104651313A (zh) | 级联激活的免疫细胞、制备方法以及应用 | |
| Smith et al. | Immunotherapy in cancer treatment | |
| CN117258131A (zh) | 载有司帕沙星和锰基纳米药物的微针贴片和在原位三阴性乳腺癌及其肺转移治疗中的应用 | |
| BR112019015785A2 (pt) | Células dendríticas plasmocitóides tendo tolerância imune e método para a produção das mesmas | |
| RU2004100550A (ru) | Способ иммунотерапии злокачественных опухолей головного мозга | |
| EP2050455A1 (en) | Compounds leading to an increase of the IL-12/IL-10 ratio and their use for therapy of infectious and proliferative diseases | |
| CN101327317B (zh) | 一种治疗肿瘤的注射液及其制备方法 | |
| US20080152626A1 (en) | Method for Activating Cd8 T Cells | |
| Nagasawa et al. | Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer | |
| CN117919384A (zh) | Il-12和替莫唑胺联用在制备治疗脑肿瘤药物的用途及组合物 | |
| US20080286315A1 (en) | Methionine Enkephalin as an Adjuvant for Vaccine Immunizations | |
| WO2023176896A1 (ja) | 糸状菌感染症の治療薬及び糸状菌感染症の治療方法 |